Duexis

Duexis is a brand name of famotidine/ibuprofen, approved by the FDA in the following formulation(s):

DUEXIS (famotidine; ibuprofen - tablet; oral)

• 
  Manufacturer: HORIZON PHARMA
  
  Approval date: April 23, 2011
  
  Strength(s): 26.6MG;800MG ^[RLD]

Has a generic version of Duexis been approved?

No. There is currently no therapeutically equivalent version of Duexis available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Duexis. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Stable compositions of famotidine and ibuprofen
  Patent 8,067,033
  Issued: November 29, 2011
  Inventor(s): Xu; Jerry & Tidmarsh; George
  Assignee(s): Horizon Pharma USA, Inc.
  Stable pharmaceutical compositions of famotidine and ibuprofen in a single unit dosage form are disclosed herein. The compositions comprise a famotidine core having a reduced or minimal surface area surrounded by a layer of ibuprofen. In some embodiments, the ibuprofen is in direct physical contact with the famotidine.
  
  Patent expiration dates:
  
  
  • July 18, 2026
    
    ✓ 
    Drug product
  
  



• 
  Methods and medicaments for administration of ibuprofen
  Patent 8,067,451
  Issued: November 29, 2011
  Inventor(s): Tidmarsh; George & Golombik; Barry L. & Sharma; Puneet
  Assignee(s): Horizon Pharma USA, Inc.
  A method for administration of ibuprofen to a subject in need of ibuprofen treatment is provided, in which an oral dosage form comprising a therapeutically effective amount of ibuprofen and a therapeutically effective amount of famotidine is administered three times per day.
  
  Patent expiration dates:
  
  
  • July 18, 2026
    
    ✓ 
    Patent use: RELIEF OF SIGNS AND SYMPTOMS OF RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS AND TO DECREASE RISK OF DEVELOPING UPPER GASTROINTESTINAL ULCERS IN PATIENTS WHO ARE TAKING IBUPROFEN FOR THOSE INDICATIONS
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 23, 2014 - NEW COMBINATION
  
  

See also...

• Duexis Consumer Information (Drugs.com)
• Duexis Consumer Information (Wolters Kluwer)
• Duexis Consumer Information (Cerner Multum)
• Duexis Advanced Consumer Information (Micromedex)
• Ibuprofen/Famotidine Consumer Information (Wolters Kluwer)
• Famotidine and ibuprofen Consumer Information (Cerner Multum)
• Ibuprofen and famotidine Advanced Consumer Information (Micromedex)